AFFILIATIONS
1 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
4 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
5 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
7 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
8 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
9 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
10 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
11 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
12 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
13 Network and Information Center of Shanghai Jiao Tong University, Shanghai, China
14 Department of Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
15 Department of Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
16 Department of Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
17 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
18 Biomedical Pioneering Innovation Center (BIOPIC) and School of Life Sciences, Beijing, China
19 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
20 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
21 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
22 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
ABSTRACT
Background
B-cell lymphoma represents approximately 85-90% of non-Hodgkin's lymphoma. Despite advances in immunotherapy, a proportion of patients still experience suboptimal responses or disease progression, highlighting the need for strategies to enhance treatment efficacy. Recent studies have underscored the role of the intratumoral microbiota in modulating the tumor microenvironment and influencing therapeutic outcomes. However, the specific mechanisms by which intratumoral microbiota impacts immunotherapy response remain poorly understood. This study aimed to investigate the role of the intratumoral microbiota in immunotherapy response in B-cell lymphoma.
Methods
Metagenomic classification was performed on samples from 281 patients with newly diagnosed follicular lymphoma who received anti-CD20 antibody rituximab (R2, n=119) or obinutuzumab (GR, n=162) plus lenalidomide. Bacteria–immune cell interactions were evaluated in vitro using a co-culture system and in vivo using murine B-cell lymphoma models. The antitumor effect of Cutibacterium acnes combined with lenalidomide was further assessed.
Results
The intratumoral microbiota landscape of follicular lymphoma was comprehensively characterized, and Cutibacterium acnes was identified as a key bacterial species associated with an immunostimulatory microenvironment and favorable outcomes in patients receiving first-line lenalidomide-based immunotherapy. Cutibacterium acnes-high patients showed significantly prolonged progression-free survival in both cohorts (R2: HR 0.22, P<0.001; GR: HR 0.41, P=0.045). RNA-seq immune deconvolution using TIP revealed significantly increased dendritic cell infiltration in Cutibacterium acnes -high tumors (P=0.021). Higher dendritic cell infiltration was also observed in patients without relapse/progression (P=0.001) and positively correlated with effector/memory CD8? T-cell infiltration. These findings identify intratumoral Cutibacterium acnes as a potential biomarker of an immune-active tumor ecosystem associated with improved disease control.
Mechanistically, Cutibacterium acnes activated STING-IFN-I signaling in dendritic cells (DCs), promoted DCs maturation and upregulation of costimulatory molecules, which in turn provoked the recruitment, proliferation, and cytotoxicity of CD8+T cells. In murine models, intratumoral Cutibacterium acnes injection remarkably inhibited B-lymphoma growth mediated by STING-IFN-I signaling activation in DCs, while the combination of Cutibacterium acnes and lenalidomide provoked a systemic tumor-suppressive effect. Therefore, Cutibacterium acnes corporates with lenalidomide in a DC-dependent manner via STING-IFN-I signaling and CD8+ T cell activation in B-cell lymphoma, providing clinical rational for reprogramming intratumoral microbiota to improve cancer immunotherapy response.
Conclusions
Our findings demonstrated a functional immunotherapeutic axis comprising microbiota and lenalidomide within the microenvironment in B-cell lymphoma, providing a rationale to improve cancer immunotherapy via reprogramming intratumoral microbiota.